Claims

1. A reagent for diagnosis and/or prognostic evaluation of carcinoma, which comprises an anti-P-LAP antibody as an active ingredient.

2. The reagent as claimed in Claim 1, wherein the carcinoma is gynecological carcinoma.

3. The reagent as claimed in Claim 2, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

4. The reagent as claimed in any one of Claims 1 to 3, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

5. The reagent as claimed in any one of Claims 1 to 3, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

6. A method for determination of P-LAP which is a prognostic factor in carcinoma, which comprises

(a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody, and

(b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody.

7. The method as claimed in Claim 6, wherein the carcinoma is gynecological carcinoma.

8. The method as claimed in Claim 7, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

9. The method as claimed in any one of Claims 6 to 8,

wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

10. The method as claimed in any one of Claims 6 to 8, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

11. A method for prognostic evaluation of carcinoma, which comprises

(a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody,

(b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and

(c) a step of correlating the intensity of the specific antigen-antibody reaction with prognosis of carcinoma.

12. The method as claimed in Claim 11, wherein the carcinoma is gynecological carcinoma.

13. The method as claimed in Claim 12, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

14. The method as claimed in any one of Claims 11 to 13, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

15. The method as claimed in any one of Claims 11 to 13, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

16. An immunoassay kit for determination of the amount of P-LAP present in carcinoma tissues obtained from carcinoma patients, which comprises an anti-P-LAP antibody and a marker enzyme for determination of the amount of the P-LAP bound to

the anti-P-LAP antibody.